

*Corporate press release*

## **Promethera Biosciences to Attend and Present at Upcoming Scientific and Partnering Conferences in March and April**

**Mont-Saint-Guibert, Belgium, March 12<sup>th</sup>, 2019** – Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that the Company will give presentations and attend the following scientific and partnering conferences in Japan, Europe, and the US.

### **18<sup>th</sup> Congress of the Japanese Society for Regenerative Medicine**

**Date:** March 21-23, 2019

**Venue:** JSRM Convention Center, Kobe, Japan

**Breakfast seminar on liver regeneration by allogenic mesenchymal stem cell therapy:**

**Session 1:** Mesenchymal stem cells derived from adult human liver: an attractive expandable cell source to target hepatic deficiencies

**Presenter:** Mustapha Najimi, Special Advisor – Scientific Affairs

**Session 2:** HepaStem, adult liver mesenchymal stem cells for liver rescue therapy in ACLF and NASH

**Presenter:** Prof. Etienne Sokal, M.D., Ph.D., CMO/CSO

**Date:** March 23<sup>rd</sup>, 2019

### **BioEurope Spring**

**Date:** March 25-27, 2019

**Venue:** Messe Wien Exhibition and Congress Center, Vienna, Austria

**Panel:**

**Title:** “What’s NEXT in NASH?”

**Presenter:** Pascale Jordan, Ph.D. Director BD, External Evaluation

**Date:** March 25<sup>th</sup>, 2019

### **The International Liver Congress™ 2019 (EASL)**

**Date:** April 10-14, 2019

**Venue:** Messe Wien Exhibition and Congress Center, Vienna, Austria

**Booth:** Biotech Village booth #6

### **3<sup>rd</sup> Annual NASH Summit in Boston**

**Date:** April 22-25, 2019

**Venue:** Hilton Boston Logan Airport, Boston, MA, USA

**Presentation:**

**Title:** “HepaStem for the treatment of fibro-inflammatory liver diseases”

**Date:** April 22, 2019

**Presenter:** Nathalie Belmonte, Ph.D., VP Product Development



### **Cell & Gene Meeting on the Mediterranean**

**Date:** April 23-25, 2019

**Venue:** Hotel Arts Barcelona, Barcelona, Spain

**Panel:**

**Title:** "Recent developments and predictions for the future of advanced therapies"

**Presenter:** John Tchelingierian, Ph.D., President & CEO

**Company presentation:**

**Title:** "HepaStem, adult liver medicinal signaling cells for liver rescue therapy in ACLF and NASH"

**Presenter:** Prof. Etienne Sokal, M.D., Ph.D., CMO/CSO

**Date:** April 24<sup>rd</sup>, 2019

### **About Promethera Biosciences**

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera®, HepaStem®, H2stem®, are all registered trademarks of the PROMETHERA group.

### **Contact Information:**

**Promethera Biosciences SA**

Alexandra Schiettekatte

[Alexandra.schiettekatte@promethera.com](mailto:Alexandra.schiettekatte@promethera.com)

Web: [www.promethera.com](http://www.promethera.com)

**For media:**

MacDougall Communications

Mario Brkulj or Shai Biran, Ph.D.

+49 89 2420 9345

or +1 781-235-3060

[promethera@macbiocom.com](mailto:promethera@macbiocom.com)



<https://www.linkedin.com/company/promethera-biosciences>



<https://twitter.com/Promethera>